Key Takeaways UBS upgraded chemicals company Chemours, arguing that the market has been too negative on the stock, which it believes can outperform. The analysts raised their rating to "buy," and increased the price target by $2. UBS said Chemours will benefit from higher profits from colorant titanium dioxide (TiO2) and demand for its next-generation refrigerants. The Chemours Co. (CC) shares gained in intraday trading Tuesday following an upgrade from UBS analysts, who said investors have been too negativ ...

Chemours (CC) shares ended the last trading session 5.5% higher at $25.56. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 16.8% loss over the past four weeks. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. Chemours is a mem ...

About This Article ■ Dear readers/followers, Sometimes the stars line up, and you manage to "catch" a company at exactly the right place. Such was the ease with Chemours during my last pices. That is why despite the recent downturn, my position in the company, and especially the one I bought at the time, is up over 22% compared to a market only up 5%. And this was back in February of this year. Seeking Alpha Chemours RoR (Seeking Alpha Chemours RoR) Chemours - An upside remains, even with the halted product ...

Carpenter Technology currently carries a Zacks Rank #1. CRS beat the Zacks Consensus Estimate in each of the last four quarters, with the average earnings surprise being 15.1%. The company's shares have soared 112.7%% in the past year. The Zacks Consensus Estimate for Ecolab's current-year earnings is pegged at $6.56 per share, indicating a year-over-year rise of 25.9%. ECL, a Zacks Rank #2 stock, beat the consensus estimate in each of the last four quarters, with the average earnings surprise being 1.3%. T ...

A month has gone by since the last earnings report for Chemours (CC) . Shares have lost about 2.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Chemours due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Chemours' Earnings Beat, Revenues Miss Estimates in Q1 Ch ...

LOS ANGELES, May 17, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC). Class Period: February 10, 2023 – February 28, 2024 Lead Plaintiff Deadline: May 20, 2024 If you are a shareholder who suffered a loss, click here to participate. The complaint filed alleges that, throughout the Class Period, Defendants failed to dis ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (NYSE: CC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Chemours and certain of its officers ...

Chemours Co (NYSE:CC) Q1 2024 Results Conference Call May 1, 2024 8:00 AM ET Company Participants Brandon Ontjes - Vice President of Investor Relations Denise Dignam - President and Chief Executive Officer Matt Abbott - Chief Financial Officer Conference Call Participants Duffy Fischer - Goldman Sachs John McNulty - BMO Capital Markets Josh Spector - UBS Financial Hassan Ahmed - Alembic Global Advisors Mike Leithead - Barclays Turner Hinrichs - Morgan Stanley Operator Good morning. My name is Lovely, and I ...

The Chemours Company (CC) logged profits of $52 million or 34 cents per share in first-quarter 2024, down from the year-ago quarter's profit of $145 million or 96 cents.Barring one-time items, earnings came in at 32 cents per share. It beat the Zacks Consensus Estimate of 25 cents.The company reported net sales of $1,350 million in the first quarter, down roughly 12% year over year. It fell short of the Zacks Consensus Estimate of $1,360.3 million. The downside was primarily attributed to a 23% decline in t ...

Chemours (CC) reported $1.35 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 12.1%. EPS of $0.32 for the same period compares to $0.98 a year ago.The reported revenue represents a surprise of -0.76% over the Zacks Consensus Estimate of $1.36 billion. With the consensus EPS estimate being $0.25, the EPS surprise was +28.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...